New treatment option for Lifestyle Factors
Official title Effect of Sleep Extension on Ceramides in People with Overweight and Obesity
ClinicalTrials.gov ID: NCT06180837
What this study is testing
- What it's testing
- The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups.
- Time commitment: about 8 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45. Healthy volunteers may be eligible.
You may be able to join if
- Age: 18-45 years old; equal numbers of men and women
- Body mass index (BMI): 27.5-34.9 kg/m2
- Sleep Habits: habitual self-reported average total sleep time (TST) \<6.5 hours per night for prior 6 months
You likely can't join if
- Clinically diagnosed sleep disorder or major psychiatric illness
- Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease)
- Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg/dL or HbA1c ≥6.5%
- Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications.
- Cancer that has been in remission less than 5 years
- Pregnant/nursing, experiencing menopause or post-menopausal
See the full eligibility criteria
- Age: 18-45 years old; equal numbers of men and women
- Body mass index (BMI): 27.5-34.9 kg/m2
- Sleep Habits: habitual self-reported average total sleep time (TST) \<6.5 hours per night for prior 6 months
- Clinically diagnosed sleep disorder or major psychiatric illness
- Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease)
- Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg/dL or HbA1c ≥6.5%
- Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications.
- Cancer that has been in remission less than 5 years
- Pregnant/nursing, experiencing menopause or post-menopausal
- Shift-work: current or history of within last year
- Weight change: \>10% of body weight over prior six months
- Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program
- Currently smoking
- Alcohol intake\>14 drinks per week or \>3 drinks per day
The study team makes the final eligibility decision.
Where it's taking place
- Salt Lake City, Utah, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 8 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 45 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Salt Lake City, Utah, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.